-
Beijing Biostar Partners with Baheal for Utidelone Market Promotion in China
•
Beijing Biostar Technologies Ltd (HKG: 2563), a synthetic biology-driven anti-tumor drug specialist that made its debut in Hong Kong last month, has entered into a market promotion service agreement with Baheal Pharmaceutical Group (SHE: 301015), a leading health services and distribution company in China. This collaboration will see Baheal provide…
-
Baheal Pharmaceutical Group Leads USD 78 Million Investment in ZAP Surgical Systems
•
Baheal Pharmaceutical Group (SHE: 301015), a leading health services and distribution company based in China, has announced its participation in a USD 78 million Series E funding round for ZAP Surgical Systems, Inc., a globally recognized leader in non-invasive robotic brain surgery. The investment will support the commercialization efforts of…
-
Baheal Pharmaceutical Group to Establish R&D Center for Myocardial Repair with CAMS Fuwai Hospital
•
BEIJING—Baheal Pharmaceutical Group, a leading healthcare services and distribution company in China, is venturing into a new collaborative endeavor with Fuwai Hospital, Chinese Academy of Medical Sciences (CAMS), to establish a joint research and development center focused on myocardial repair and regeneration drugs. This initiative comes in response to the…
-
Baheal Pharmaceutical Group to Launch Industry Fund Focused on Life Sciences
•
China’s leading health services and distribution conglomerate, Baheal Pharmaceutical Group, is venturing into the investment space with the establishment of a new industry fund. This fund is designed to target opportunities in the life sciences and healthcare sectors. In a collaborative effort, Baheal will be partnering with a consortium that…
-
Baheal Pharmaceutical Group Enters Commercialization Partnership with Guangdong Ruidio Technology
•
China-based health services and distribution giant Baheal Pharmaceutical Group has struck a commercialization partnership with Guangdong Ruidio Technology Co., Ltd. Under the terms of the agreement, Baheal acquires commercialization rights to Ruidio’s series of radioactive drugs, including 99mTc-3PRGD2, 99mTc-HP-Ark2, and 99mTc-POFAP, as well as imaging equipment products such as SPECT.…
